OPTOFLUID TECHNOLOGIES OÜ

Their core work

Optofluid Technologies is an Estonian medical device SME developing online monitoring sensors for hemodialysis treatment. Their core product, OLDIAS, is a real-time dialysis sensor that measures treatment adequacy during the procedure itself — replacing the standard practice of waiting for post-treatment lab results. The company name points to their technical approach: combining optical measurement with microfluidics to extract clinical signals directly from the dialysate stream. For clinicians, this means faster decisions; for dialysis clinics, it means measurable quality improvements for kidney patients.

What they specialise in

How they've shifted over time

Optofluid followed a textbook SME Instrument trajectory: a EUR 50,000 feasibility study in 2015 (OLDIAS) was followed two years later by a EUR 2.8M Phase 2 grant (OLDIAS2, 2017-2019) to industrialize the same product. The focus did not shift — it deepened, moving from concept validation to prototype, clinical testing, and market preparation for the online dialysis sensor. Since 2019 they have not appeared in new H2020 projects, suggesting the company has either entered commercial deployment or is pursuing non-EU funding paths.

Having completed SME Phase 2 in 2019, they are likely in product launch or clinical rollout mode — a good partner for clinical validation studies or distribution partnerships, less likely to be building fresh R&D consortia.

How they like to work

Optofluid operates as a solo SME grant recipient rather than a consortium player — both projects are coordinated alone with no listed consortium partners in the H2020 record. This is normal for the SME Instrument scheme, which funds single companies rather than multi-party consortia. For partners, this means engaging them is a direct commercial conversation, not a negotiation through a larger research network.

No formal consortium partners appear in their H2020 record because both projects used the single-beneficiary SME Instrument. Their operational base is Tallinn, Estonia, with no multi-country project work indicated.

What sets them apart

Optofluid is one of very few Estonian medtech SMEs to have cleared the competitive SME Instrument Phase 1 → Phase 2 gate with a single focused product. Unlike diversified medical device firms, they have one clearly defined technology — optical online measurement in the dialysis circuit — which makes them easy to evaluate and engage for a specific clinical or industrial question. Partner with them if you are working in renal care, dialysis clinic quality monitoring, or point-of-care biosensing.

Highlights from their portfolio

• OLDIAS2
  EUR 2.8M SME Instrument Phase 2 grant — their largest project and the step that took their dialysis sensor from feasibility to industrial development.
• OLDIAS
  The Phase 1 feasibility study that seeded the whole product line; a textbook example of the SME Instrument pipeline working as intended.